Diovan to reduce the mortality by 33% in patients with cardiac faiure

Published: 2002-04-03 06:58:00

Updated: 2002-04-03 06:58:00

In the recently conducted large trials 'Val-HeFT (valsartan Heart Failure Trial)' to evaluate the efficacy of angiotensin II inhibitor 'valsartan' in 5,010 patients (302 centers in 16 countries) with cardiac failure receiving the conventional medication including beta-blocker, diurectic, digoxin ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK